Nephrology

British Medical Journal

Volumn 320, Issue 7227, 2000, Pages 98-101

  Tomson, C R V ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; CALCIUM; SODIUM;

CALCIUM TRANSPORT; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; FLUID BALANCE; GLOMERULONEPHRITIS; HUMAN; HYPERPARATHYROIDISM; HYPONATREMIA; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; NEPHROLOGY; PRIORITY JOURNAL; PROTEINURIA; SHORT SURVEY; VASCULITIS; FORECASTING; ISCHEMIA; KIDNEY; METABOLISM; REVIEW; VASCULARIZATION;

CALCIUM; DIABETIC NEPHROPATHIES; FORECASTING; GLOMERULONEPHRITIS; HUMANS; ISCHEMIA; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; POLYCYSTIC KIDNEY DISEASES; SODIUM; VASCULITIS;

EID: 0034620179     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (43)

1. Connolly DL, Shanahan CM, Weissberg PL. Water channels in health and disease. Lancet 1996;347:210-2.
2. Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996;50:2129-39.
3. 2+ on parathyroid and kidney cells? Kidney Int 1996;49:1042-6.
4. Silverberg SJ, Bone HG, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997;337:1506-10.
5. Nemeth EF, Bennett SA. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 1988;13:1923-5.
6. Lifton RP. Molecular genetics of blood pressure variation. Science 1996;272:676-80.
7. Cusi D, Bianchi G. A primer on the genetics of hypertension. Kidney Int 1998;54:328-42.
8. Kurtz T. Molecular pathogenesis of Bartter's and Gitelman's syndromes. Kidney Int 1998;45:1396-410.
9. Allen AC, Harper S, Feehally J. Origin and structure of pathogenic IgA in IgA nephropathy. Biochem Soc Trans 1997;25:486-90.
10. Allen AC, Willis FR, Beattie J, Feehally J. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 1998;1998:930-4.
11. Donadio JV. Immunoglobulin A nephropathy: a clinical perspective. J Am Soc Nephrol 1997;8:1324-32.
12. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial [see comments]. Lancet 1999;353:883-7.
13. Iseki K, Iseki C, Ikeyima Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996;49:800-5.
14. Harris PC, Ward CJ, Peral B, Hughes J. Polycystic kidney disease 1: identification and analysis of the primary defect. J Am Soc Nephrol 1995;6:1125-33.
15. Harris PC, Watson ML. Autosomal dominant polycystic kidney disease: neoplasia in disguise? Nephrol Dial Transplant 1997;12:1089-90.
16. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997;8:1560-7.
17. Geberth S, Stier E, Zeier M, Mayer G, Rambausek M, Ritz E. More adverse renal prognosis of autosomal dominant polycystic kidney disease in families with primary hypertension. J Am Soc Nephrol 1995;6:1643-8.
18. Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995;5:2037-47.
19. Khan IH, Catto G, Edward N, MacLeod AM. Death during the first 90 days of dialysis: a case control study. Am J Kidney Dis 1995;25:276-80.
20. Ismail N, Neyra R, Hakim R. The medical and economical advantages of early referral of chronic renal failure patients to renal specialists. Nephrol Dial Transplant 1998;13:246-50.
21. Kunz R, Bork JP, Fritzsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998;9:1653-63.
22. Ruggenenti P, Gaspari F, Oerna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998;16:504-9.
23. Van der Kleij FGH, Schmidt AA, Navis GJ, Haas M, Yilmaz N, de Jong PE, et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int 1998;53(suppl 63):23-6S.
24. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
25. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.
26. Maschio G, Alberti D, Janin G, Locatelli FF, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor Benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
27. The Gruppo Italiano di Studi Epidemiologici in Nefrologia Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
28. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.
29. Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. J Hum Hypertens 1992;6(suppl 2):523-36.
30. Sawicki PT. Do ACE inhibitors offer specific benefits in the antihypertensive treatment of diabetic patients? Diabetologia 1998;41:598-602.
31. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
32. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomizzed trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
33. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
34. Devoy MAB, Tomson CRV, Edmunds ME, Feehally J, Walls J. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992;232:493-8.
35. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997;15:1365-77.
36. Mikhail A, Cook GJR, Reidy J, Scoble JE. Progressive renal dysfunction despite successful renal artery angioplasty in a single kidney. Lancet 1997;349:926.
37. Vidt DG, Eisele G, Gephardt GN, Tubbs R, Novick AC. Atheroembolic renal disease: association with renal arterial stenosis. Cleve Clin J Med 1988;56:407-13.
38. Rhodes JM. Cholesterol crystal embolism: an important "new" diagnosis for the general physician. Lancet 1996;347:1641.
39. Missouris CG, Buckenham T, Vallance PJT, MacGregor GA. Renal artery stenosis masquerading as congestive heart failure. Lancet 1993;341:1521-2.
40. Ramsay LE, Waller PC. Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. BMJ 1990;300:569-72.
41. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 1993;118:712-9.
42. Krumholz HM. Time to focus on the more typical heart-failure patients. Lancet 1998;352:3-4.
43. Kestila M, Lenkkeri U, Manniko M, Lamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998;1:575-82.